Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (DE:29A)
FRANKFURT:29A
RESEARCH TOOLSreports
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 712.81M | $ 644.39M | $ 498.99M | $ 437.77M | $ 349.85M |
| Gross Profit | $ 373.86M | $ 351.12M | $ 248.86M | $ 199.74M | $ 143.34M |
| Operating Income | $ 205.42M | $ 196.99M | $ 78.76M | $ 43.13M | $ -14.23M |
| EBITDA | $ 277.31M | $ 240.29M | $ 107.50M | $ 111.78M | $ 30.19M |
| Net Income | $ 159.52M | $ 137.54M | $ 91.39M | $ 62.12M | $ 1.10M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 221.65M | $ 256.81M | $ 175.76M | $ 136.67M | $ 105.62M |
| Total Assets | $ 1.58B | $ 1.51B | $ 741.99M | $ 671.53M | $ 631.24M |
| Total Debt | $ 48.92M | $ 623.64M | $ 102.58M | $ 104.66M | $ 67.27M |
| Net Debt | $ -102.69M | $ 479.35M | $ -53.52M | $ -21.69M | $ -25.37M |
| Total Liabilities | $ 845.17M | $ 873.49M | $ 213.33M | $ 226.01M | $ 182.51M |
| Stockholders' Equity | $ 732.30M | $ 639.42M | $ 528.66M | $ 445.52M | $ 402.31M |
| Cash Flow | |||||
| Free Cash Flow | $ 172.34M | $ 145.34M | $ 65.15M | $ 70.54M | $ 23.41M |
| Operating Cash Flow | $ 213.39M | $ 183.50M | $ 89.18M | $ 97.99M | $ 57.27M |
| Investing Cash Flow | $ -124.93M | $ -649.12M | $ -32.78M | $ -28.67M | $ -36.41M |
| Financing Cash Flow | $ -80.95M | $ 454.09M | $ -26.44M | $ -37.02M | $ -2.25M |